PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23337792-1 2012 Our previous study demonstrated that the peroxisome proliferator-activated receptor (PPAR) gamma agonist, pioglitazone (PIO), may be cardioprotective against ischemia-reperfusion injury; however, modulation of p42/p44 extracellular signal-regulated kinases (ERK1/2) and cyclooxygenase (COX)-2 by PIO in the myocardium with respect to ischemia-reperfusion (I/R) is only partially understood. Pioglitazone 106-118 peroxisome proliferator activated receptor alpha Rattus norvegicus 41-83 24471407-2 2014 Pioglitazone is a peroxisome proliferator-activated receptor (PPAR) gamma agonist and, although it is mostly used as an antidiabetic agent, it has been reported to have analgesic effects. Pioglitazone 0-12 peroxisome proliferator activated receptor alpha Rattus norvegicus 18-60 24471407-2 2014 Pioglitazone is a peroxisome proliferator-activated receptor (PPAR) gamma agonist and, although it is mostly used as an antidiabetic agent, it has been reported to have analgesic effects. Pioglitazone 0-12 peroxisome proliferator activated receptor alpha Rattus norvegicus 62-66 23337792-1 2012 Our previous study demonstrated that the peroxisome proliferator-activated receptor (PPAR) gamma agonist, pioglitazone (PIO), may be cardioprotective against ischemia-reperfusion injury; however, modulation of p42/p44 extracellular signal-regulated kinases (ERK1/2) and cyclooxygenase (COX)-2 by PIO in the myocardium with respect to ischemia-reperfusion (I/R) is only partially understood. Pioglitazone 106-118 peroxisome proliferator activated receptor alpha Rattus norvegicus 85-89 22062085-1 2012 Peroxisome proliferator-activated receptor (PPAR) gamma agonists, such as pioglitazone (Pio), improve glycemia and lipid profile but are associated with bone loss and fracture risk. Pioglitazone 74-86 peroxisome proliferator activated receptor alpha Rattus norvegicus 0-42 22062085-1 2012 Peroxisome proliferator-activated receptor (PPAR) gamma agonists, such as pioglitazone (Pio), improve glycemia and lipid profile but are associated with bone loss and fracture risk. Pioglitazone 74-86 peroxisome proliferator activated receptor alpha Rattus norvegicus 44-48 22062085-1 2012 Peroxisome proliferator-activated receptor (PPAR) gamma agonists, such as pioglitazone (Pio), improve glycemia and lipid profile but are associated with bone loss and fracture risk. Pioglitazone 88-91 peroxisome proliferator activated receptor alpha Rattus norvegicus 0-42 22062085-1 2012 Peroxisome proliferator-activated receptor (PPAR) gamma agonists, such as pioglitazone (Pio), improve glycemia and lipid profile but are associated with bone loss and fracture risk. Pioglitazone 88-91 peroxisome proliferator activated receptor alpha Rattus norvegicus 44-48 21316363-1 2011 In a recent issue of Experimental Neurology, Sauerbeck and colleagues demonstrated that treatment with the peroxisome proliferator-activated receptor (PPAR) agonist Pioglitazone after experimental traumatic brain injury (TBI) in rats was protective against mitochondrial dysfunction, cognitive impairment, cortical tissue loss and microglial activation. Pioglitazone 165-177 peroxisome proliferator activated receptor alpha Rattus norvegicus 107-149 21316363-1 2011 In a recent issue of Experimental Neurology, Sauerbeck and colleagues demonstrated that treatment with the peroxisome proliferator-activated receptor (PPAR) agonist Pioglitazone after experimental traumatic brain injury (TBI) in rats was protective against mitochondrial dysfunction, cognitive impairment, cortical tissue loss and microglial activation. Pioglitazone 165-177 peroxisome proliferator activated receptor alpha Rattus norvegicus 151-155 29554649-0 2018 Pioglitazone Confers Neuroprotection Against Ischemia-Induced Pyroptosis due to its Inhibitory Effects on HMGB-1/RAGE and Rac1/ROS Pathway by Activating PPAR- . Pioglitazone 0-12 peroxisome proliferator activated receptor alpha Rattus norvegicus 153-157 20965168-3 2011 In the current study we hypothesized that treatment with the PPAR ligand Pioglitazone would promote neuroprotection following a rat controlled cortical impact model of TBI. Pioglitazone 73-85 peroxisome proliferator activated receptor alpha Rattus norvegicus 61-65 20965168-14 2011 These studies provide further support for the use of PPAR ligands, specifically Pioglitazone, for neuroprotection. Pioglitazone 80-92 peroxisome proliferator activated receptor alpha Rattus norvegicus 53-57 32353564-7 2020 Compound 9n and 9a were found to be most potent on both PPAR alpha and gamma receptors with EC50 of 0.07 +- 0.0006 microM, 0.06 +- 0.0005 microM and 0.781 +- 0.008 microM, 3.29 microM +- 0.03 respectively as better to pioglitazone having EC50 of 32.38 +- 0.2 and 38.03 +- 0.13 for both receptors. Pioglitazone 218-230 peroxisome proliferator activated receptor alpha Rattus norvegicus 56-66 17343847-13 2007 The results represent the first demonstration of the antinociceptive and antiedematogenic activities of fenofibrate and pioglitazone and give further support to the potential use of PPAR agonists in the treatment of different inflammatory diseases. Pioglitazone 120-132 peroxisome proliferator activated receptor alpha Rattus norvegicus 182-186 11272155-10 2001 We conclude that even though WY14643 and pioglitazone, representing PPAR-alpha and PPAR-gamma activation, respectively, may alter muscle lipid supply by different mechanisms, both significantly improve muscle insulin action in the high fat-fed rat model of insulin resistance, and this effect is proportional to the degree to which they reduce muscle lipid accumulation. Pioglitazone 41-53 peroxisome proliferator activated receptor alpha Rattus norvegicus 68-78 26536032-7 2015 Immunostaining showed that renal expressions of PPARalpha and PPARgamma were reduced by cisplatin and restored to vehicle-treated values after simultaneous treatment with pioglitazone or fenofibrate. Pioglitazone 171-183 peroxisome proliferator activated receptor alpha Rattus norvegicus 48-57